Kevin Fox, MD
Ultima Vez Modificado: 20 de enero del 2002
Dear OncoLink "Ask The Experts,"
My sister has stage IV breast cancer and is being treated with Herceptin and Tamoxifen. Assuming the treatment continues to work effectively, is taking Herceptin long after the chemotherapy treatment is over considered risky?
Kevin Fox, MD Assistant Director, Clinical Affairs and Associate Professor of Hematology/Oncology at the Abramson Cancer Center of the University of Pennsylvania, responds:
The safety of long-term Herceptin treatment is unknown because the medication is so new. The longest stretches of Herceptin treatment alone reported in the literature approach two years. Unanticipated problems have not emerged to date, but studies are ongoing. We generally recommend close cardiac monitoring with evaluation of ejection fraction every two to three months because cardiac toxicity has been reported in patients receiving chemotherapy at the same time as Herceptin.
Oct 24, 2011 - For postmenopausal women with hormone receptor-positive early breast cancer, letrozole monotherapy reduces breast cancer recurrence and mortality in the long-term more effectively than tamoxifen monotherapy, according to a study published online Oct. 21 in The Lancet Oncology.
Jul 31, 2014
Jun 14, 2010
Jul 31, 2014